Kabi Awaits Melrose Park Fate As mAbxience Deal Closes

€455m Deal For 55% Stake In Biosimilars Business Closed 1 August

NicoElNino/Alamy Stock Photo
Kabi now holds a 55% stake in mabxience • Source: Shutterstock (NicoElNino / Alamy Stock Photo/Alamy Stock Photo)

More from Biosimilars

More from Products